Lantern Pharma (LTRN) Investor Update summary

AI-driven drug development and platform advancements

• Leveraging AI and data-driven approaches to accelerate and de-risk oncology drug development, with a focus on precision medicines and combination therapies.

• Public release of PredictBBB.ai, a module predicting blood-brain barrier penetrability, with further modules planned to expand predictive capabilities for drug properties.

• AI platform RADR is central to both internal drug development and external collaborations, with a freemium model to drive adoption and future revenue.

• AI modules are expected to generate partnerships and transform drug discovery, with ongoing discussions for external use in CNS drug screening.

• The platform's predictive power is based on analyzing thousands of molecular features, aiming to revolutionize molecule assessment and drug development.

Clinical pipeline and trial updates

• Three main clinical assets: LP-300 (phase II, never-smoker NSCLC), LP-184 (phase I completed, solid tumors), and LP-284 (in trials for B-cell lymphomas).

• LP-300 shows durable complete responses in never-smoker NSCLC, with expansion into Japan and Taiwan due to high incidence rates.

• LP-184 demonstrated strong potency in phase I, with phase I-B/II trials planned for TNBC, bladder, and STK11/KEAP1-mutated lung cancers.

• LP-284 achieved a complete metabolic response in a heavily pretreated high-grade B-cell lymphoma patient, supporting further development.

• Combination therapy strategies are being pursued, especially with PARP inhibitors and checkpoint inhibitors, to enhance efficacy and durability.

Financial and operational highlights

• Maintains a disciplined fiscal profile with a quarterly burn rate of $4.5 million and cash runway into mid-2026.

• No debt, no warrants, and approximately 10.8 million shares outstanding.

• Business model centers on early innovation, clinical execution, and out-licensing assets to larger pharma partners.